Please enter your license information:
Coverage
Trajenta® and Jentadueto® are reimbursed across Canada (restrictions apply).16–30
![NIHB NIHB](https://pro.boehringer-ingelheim.com/ca/products/trajenta//images/map_pins_nihb.png)
Trajenta®16
Step Therapy/Special Authorization
FIRST-LINE DRUG PRODUCT(S): METFORMIN
SECOND-LINE DRUG PRODUCT(S): SULFONYLUREAS
AND WHERE INSULIN IS NOT AN OPTION
As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:
- a sufficient trial (i.e., a minimum of 6 months) of metformin, AND
- a sulfonylurea, AND
- for whom insulin is not an option
Or, for whom these products are contraindicated.
Special authorization may be granted for 24 months.
Jentadueto®16
Step Therapy/Special Authorization
FIRST-LINE DRUG PRODUCT(S): METFORMIN
SECOND-LINE DRUG PRODUCT(S): SULFONYLUREAS
AND WHERE INSULIN IS NOT AN OPTION
As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:
- a sufficient trial (i.e., a minimum of 6 months) of metformin, AND
- a sulfonylurea, AND
- for whom insulin is not an option
Or, for whom these products are contraindicated.
Special authorization may be granted for 24 months.
Trajenta®17
Limited Coverage
As part of a combination treatment for type 2 diabetes mellitus:
After inadequate glycemic control on maximum tolerated doses of dual therapy of metformin AND a sulfonylurea or dual therapy of metformin and an insulin.
Special Notes:
- Patients intolerant to a sulfonylurea may be considered for coverage. Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the PharmaCare Special Authority program).
- Patients who meet the Limited Coverage criteria for linagliptin automatically receive coverage for saxagliptin.
Jentadueto®17
Limited Coverage
As part of a combination treatment for type 2 diabetes mellitus:
After inadequate glycemic control on maximum tolerated doses of dual therapy of metformin AND a sulfonylurea or dual therapy of metformin and an insulin.
Special Notes:
- Patients intolerant to a sulfonylurea may be considered for coverage. Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the PharmaCare Special Authority program).
- Patients who meet the Limited Coverage criteria for linagliptin automatically receive coverage for saxagliptin.
Trajenta®18
Exceptional Drug Status
For the treatment of patients with type 2 diabetes who have previously been treated with metformin and a sulfonylurea. Should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option.
Jentadueto®18
Exceptional Drug Status
For type 2 diabetic patients who have been titrated to a stable combination, for a minimum of at least 3 months, of the separate components, metformin and linagliptin, and for whom insulin is not an option.
Trajenta®19
Covered in New Brunswick
For the treatment of type 2 diabetes mellitus when added to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea and in whom insulin is not an option.
Clinical Note:
- For patients who cannot take metformin and/or a sulfonylurea due to contraindications or intolerances, details must be provided
Jentadueto®19
Special Authorization
For the treatment of type 2 diabetes mellitus in patients who are already stabilized on therapy with linagliptin and metformin, to replace the individual components of linagliptin and metformin.
Trajenta®20
Special Authorization
For the treatment of type 2 diabetes as a third drug added to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea AND in whom insulin is not an option.
Jentadueto®20
Special Authorization
For the treatment of type 2 diabetes in patients who are already stabilized on therapy with metformin, a sulfonylurea and linagliptin to replace the individual components of linagliptin and metformin AND for whom insulin is not an option.
Trajenta®22
Matches NIHB
Open benefit with therapeutic notes
For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.
Jentadueto®23
Matches NIHB
Open benefit with therapeutic notes
For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.
Trajenta®21
Exception Status Drug
For the treatment of Type II diabetes for patients with:
- inadequate glycemic control on metformin and a sulfonylurea; and
- for whom insulin is not an option
Jentadueto®21
Exception Status Drug
For the treatment of Type II diabetes for patients:
- who are already stabilized on therapy with metformin, a sulfonylurea and linagliptin to replace the individual components of linagliptin and metformin; and
- for whom insulin is not an option
Trajenta®22
Matches NIHB
Open benefit with therapeutic notes
For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.
Jentadueto®23
Matches NIHB
Open benefit with therapeutic notes
For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.
Trajenta®24
General benefit with therapeutic notes
Treatment of type 2 diabetes in patients on maximally tolerated doses of metformin who have:
- Inadequate glycemic control (defined as HbA1c >0.07) and intolerance or contraindication to a sulfonylurea; OR
- Inadequate glycemic control (HbA1c >0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option
Jentadueto®24
General benefit with therapeutic notes
Treatment of type 2 diabetes in patients on maximally tolerated doses of metformin who have:
- Inadequate glycemic control (defined as HbA1c >0.07) and intolerance or contraindication to a sulfonylurea; OR
- Inadequate glycemic control (HbA1c >0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option
Trajenta®25
Special Authorization
For the treatment of type 2 diabetes as a third drug added on to metformin and a sulfonylurea for patients with inadequate glycemic control on optimal doses of metformin and a sulfonylurea, and for whom insulin is not an option.
Jentadueto®25
Special Authorization
For patients with type 2 diabetes for whom insulin is not an option and who are already stabilized on therapy with metformin, a sulfonylurea and linagliptin, to replace the individual components of linagliptin and metformin in these patients.
Trajenta®22,26,27
Exceptional Medication
- For treatment of type 2 diabetic persons:
- as monotherapy when metformin and a sulfonylurea are contraindicated or poorly tolerated;
or
- in association with metformin where a sulfonylurea is contraindicated, not tolerated or ineffective
- Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.
EN148
For the treatment of persons with type 2 diabetes in combination with metformin where a sulfonylurea is contraindicated, not tolerated or ineffective. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.
EN167
For the treatment of persons with type 2 diabetes in monotherapy when metformin and a sulfonylurea are contraindicated or not tolerated.
Jentadueto®23,26,27
Exceptional Medication
- For treatment of type 2 diabetic persons:
- where a sulfonylurea is contraindicated, not tolerated or ineffective;
and
- where the optimal maximum dose of metformin has been stable for at least one month
- Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.
EN150
For the treatment of people with type 2 diabetes:
- when a sulfonylurea is contraindicated, not tolerated or ineffective;
and
- when the optimal maximum dose of metformin has been stable for at least one month.
- Ineffectiveness refers to a failure to achieve the value of glycated hemoglobin (HbA1c) adapted to the patient.
Trajenta®28
Exception Drug Status
For treatment of patients with Type 2 diabetes who are not adequately controlled on, or are intolerant to, metformin AND a sulfonylurea.
Jentadueto®28
Exception Drug Status
For treatment of patients with Type 2 diabetes who are not adequately controlled on, or are intolerant to, metformin AND a sulfonylurea.
Trajenta®29
Exception Criteria
Type 2 Diabetes
As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on:
- a sufficient trial (i.e. a minimum of 6 months) of metformin, AND
- a sulfonylurea, AND
- for whom insulin is not an option (for reason other than needle phobia) OR
- for whom these products are contraindicated
Jentadueto®29
Exception Criteria
For combination treatment of type 2 diabetes for patients approved for linagliptin coverage and already stabilized on combination treatment with metformin.
Trajenta®30
Open benefit with therapeutic notes
For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.
Jentadueto®30
Open benefit with therapeutic notes
For the treatment of patients with type 2 diabetes mellitus who did not achieve glycemic control or who demonstrated intolerance to an adequate trial of metformin and a sulfonylurea.
Jentadueto® (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus who are inadequately controlled on metformin, or already controlled with the free combination of linagliptin and metformin.15
Jentadueto® (linagliptin/metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with a sulfonylurea, when dual therapy with metformin and a sulfonylurea do not provide adequate glycemic control, or in combination with basal insulin, when dual therapy with metformin and basal insulin do not provide adequate glycemic control.15
Please refer to the Product Monograph at www.JentaduetoPM.ca for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-263-5103 ext. 84633.
-
HbA1c=glycated hemoglobin.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)